NY-TRG
11.3.2021 19:26:05 CET | Business Wire | Press release
The Rohatyn Group (“TRG”), a global, US-based asset management firm, today announced that it has completed an investment in the specialized pet accessories company MyFamily Srl (“MyFamily” or the “Company”), establishing a partnership with the Company’s founder, Alessandro Borgese, and existing investors including 035 investimenti S.p.A. TRG’s investment will allow MyFamily to accelerate its product rollout and continue expanding its global distribution channels. Terms of the transaction were not disclosed.
Founded in 2011 in Valenza, Italy, MyFamily is a global producer of engravable pet ID tags and tag engraving machines. The Company’s engraving machines are present in approximately 9,000 retail locations in more than 70 countries worldwide. The Company has recently expanded its pet accessories assortment through a unique range of pet collars, leashes and harnesses, including the technology-enabled Memopet collection, which offers a differentiated smart and interactive experience.
“MyFamily is a highly attractive business that provides a unique product offering in the global pet accessories sector. We believe the Company is well positioned to benefit from accelerated premiumization of pet products and deliver strong growth as the global pet accessories market continues to expand,” said TRG’s Colin Clark, Head of the EMEA Private Markets investment team, and Stepan Karpukhin, Managing Director.
TRG’s Harold Chatelus, who will immediately join the Board of Directors of MyFamily, added, “Alessandro Borgese leads a highly qualified and motivated global management team, whose dedication to product innovation is evident in the quality and design leadership of MyFamily’s product portfolio. TRG will actively support the Company’s expansion strategy with the goal of enhancing scale and solidifying global market leadership.”
Nick Rohatyn, CEO of TRG added, “MyFamily is a high-growth business with international access that fits in perfectly with TRG’s global approach. We believe strongly that the Company has the potential to transform the global pet accessories sector thanks to its innovative and technology-forward strategy. Our investment team will seek to leverage our deep knowledge of the pet care industry and positive experience from current portfolio company Pet Network International to assist Alessandro and his talented team in achieving their growth objectives.”
Alessandro Borgese, founder and CEO of MyFamily, commented, “I am tremendously proud of the growth MyFamily has already achieved, particularly over the last two years, as we have transformed our product portfolio, invested greatly in production quality and automation, and expanded our distribution network following the launch of our US subsidiary. TRG’s investment will accelerate the next phase in MyFamily’s development. We look forward to continuing our growth in partnership with The Rohatyn Group and leveraging the team’s expertise.”
About TRG
Founded in 2002, The Rohatyn Group is an emerging markets focused asset management firm headquartered in New York, with a presence around the globe including Boston, Buenos Aires, Montevideo, Lima, São Paulo, San Jose, London, Cairo, Mumbai, New Delhi, Singapore, Hanoi, Kuala Lumpur and Rotorua. For more information, please visit www.rohatyngroup.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210311005900/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IQM and Deutsche Bahn Demonstrate Quantum Algorithm for Railway Scheduling on Real Operational Data20.7.2026 08:00:00 CEST | Press release
A hybrid quantum-classical algorithm, executed end to end on IQM hardware, produced feasible schedules with Deutsche Bahn, the German rail operator, using a real operational dataset of 190 trips across five German cities. The approach runs on today’s hardware and is designed to improve automatically as quantum processors scale, offering enterprises a model for extracting value now, ahead of fault-tolerant computing. The collaboration reflects IQM’s push into enterprise adoption. The company has sold 24 quantum computers worldwide and listed on the Nasdaq Global Select Market and Nasdaq Helsinki in July 2026 under the ticker IQMX. IQM Quantum Computers (Nasdaq: IQMX), a global leader in full-stack superconducting quantum computers, today published the results of a research collaboration with Deutsche Bahn, Europe’s largest rail operator, exploring how quantum computing can improve railway scheduling. This press release features multimedia. View the full release here: https://www.busines
Galderma Launches Alastin® in Japan and Key Markets Across Asia Pacific, Expanding Its Footprint in the Region20.7.2026 07:00:00 CEST | Press release
Galderma launches Alastin, its premium regenerative skincare brand into Japan, Singapore, South Korea and Taiwan The Japan and Asia Pacific (JPAC) region is among the fastest‑growing markets globally for medical aesthetics and dermatological skincare, driven by rising adoption of minimally invasive procedures and an increased focus on skin quality, which are accelerating demand for innovative, science‑based skincare solutions such as Alastin1,2 These launches reflect Galderma’s ongoing growth across the JPAC region and long‑term commitment to advancing regenerative skincare Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the launch of Alastin – its premium regenerative skincare brand – across the JPAC region. The brand recently launched in Taiwan, will soon launch in Japan, and has received approval to launch in Singapore and South Korea, with planned market introduction in September and November, respectively. This expansion follows Alastin’s recent la
Incyte Data to Be Highlighted in Four Rapid Oral Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 Support Efforts to Improve Outcomes in Difficult-to-Treat Cancers17.7.2026 19:10:00 CEST | Press release
Rapid oral presentations will highlight new Phase 1 data across Incyte’s solid tumor portfolioBoth INCB161734, an investigational, potent, selective and orally bioavailable KRAS G12D inhibitor, and INCA338901, a TGFβR2×PD-1 bispecific antibody, are being evaluated in ongoing Phase 3 programs as first-line treatments for patients with advanced pancreatic ductal adenocarcinoma (PDAC) and microsatellite stable (MSS) colorectal cancer, respectively Incyte (Nasdaq:INCY) today announced that it will highlight data from several programs in its oncology portfolio in six presentations at the European Society of Medical Oncology (ESMO) Congress 2026, being held October 23 - 27, 2026, in Madrid. “The data at ESMO will further illustrate Incyte’s commitment to advancing innovation for patients with cancer,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "Among the presentations are important updates from our KRAS G12D inhibitor in advanced pancreatic ca
STL Expands Its Optical Connectivity Portfolio in the US with the CONCAT Solution17.7.2026 14:24:00 CEST | Press release
STL Optical Connectivity NA, LLC, (STLOC), a U.S. subsidiary of STL (Sterlite Technologies Ltd.) [NSE: STLTECH], a leading connectivity solutions provider for AI-ready digital infrastructure, today announced that it launched its new advanced FTTH solution, CONCAT, after successfully completing field trials on the networks of one of the largest telecom service providers in the United States. Following successful field validation, CONCAT is now available to digital infrastructure providers seeking faster fiber rollouts with reduced deployment complexity and labor. It enables up to 71% in labor cost savings by eliminating most field splicing through factory-assembled, pre-connectorized fiber segments that deliver plug-and-play installation. CONCAT simplifies fiber deployment by shifting critical fiber preparation and termination into a controlled manufacturing environment ensuring consistent quality, faster installation, and lower operational risk in the field. CONCAT solution is ideal fo
Aqemia and Sanofi Expand Their Research Collaboration17.7.2026 12:30:00 CEST | Press release
A new target nomination and a milestone payment mark the next step of the multi-year partnership first announced in December 2023 Aqemia, the drug invention company combining generative AI and quantum-inspired physics to invent small molecule drugs, today announced the expansion of its multi-year research collaboration with the global pharmaceutical company, Sanofi. The expansion is marked by the nomination of a new therapeutic target and an additional payment. The collaboration, first announced in December 2023, makes Aqemia eligible to receive up to a total of $140 million in upfront and milestone payments across programs. It spans the drug discovery journey from the identification of the very first hits to the selection of a development candidate. Aqemia leverages Qemi, its proprietary physics-based generative AI platform, to design novel molecules addressing Sanofi’s targets of choice, working in close collaboration with Sanofi scientific teams. Sanofi leads wet lab research, devel
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom